


CLAIMS

We claim:

1. A compound of formula (1) or a pharmaceutically acceptable salt thereof:



formula (1)

wherein:

 Y^1 and Y^2 are independently O or S;z is NR^8 , O or S;

- 10 n is 0 or 1;

W is NR^1 , CR^1R^2 or a bond;

m is 0 or 1;

D is hydrogen, C_{1-4} alkyl, C_{3-6} cycloalkyl or fluoro;X is $-(CR^{12}R^{13})_t-Q-(CR^{14}R^{15})_u-$ where t and u are independently 0 or 1 and Q is O, S, SO or

- 15 SO_2 ;

B is a group selected from aryl, heteroaryl and heterocyclyl, where each group is optionally substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo, cyano, C_{1-4} alkyl (optionally substituted by R^9 or C_{1-4} alkoxy or one or more halo), C_{2-4} alkenyl (optionally substituted by halo or R^9), C_{2-4} alkynyl (optionally substituted by halo or R^9), C_{3-6} cycloalkyl (optionally substituted by R^9 or one or more halo), C_{5-6} cycloalkenyl (optionally substituted by halo or R^9), aryl (optionally substituted by halo or C_{1-4} alkyl), heteroaryl (optionally substituted by halo or C_{1-4} alkyl), heterocyclyl (optionally substituted by C_{1-4} alkyl), $-SR^{11}$, $-SOR^{11}$, $-SO_2R^{11}$, $-SO_2NR^9R^{10}$, $-NR^9SO_2R^{11}$, $-NHCONR^9R^{10}$, $-OR^9$, $-NR^9R^{10}$, $-CONR^9R^{10}$ and $-NR^9COR^{10}$; or B is C_{2-4} alkenyl or C_{2-4} alkynyl, each being optionally substituted by a group selected from C_{1-4} alkyl, C_{3-6} cycloalkyl, aryl, heteroaryl and heterocyclyl which group is optionally substituted by one or more halo,

- 20 substituted by halo or R^9 , C_{3-6} cycloalkyl (optionally substituted by R^9 or one or more halo), C_{5-6} cycloalkenyl (optionally substituted by halo or R^9), aryl (optionally substituted by halo or C_{1-4} alkyl), heteroaryl (optionally substituted by halo or C_{1-4} alkyl), heterocyclyl (optionally substituted by C_{1-4} alkyl), $-SR^{11}$, $-SOR^{11}$, $-SO_2R^{11}$, $-SO_2NR^9R^{10}$, $-NR^9SO_2R^{11}$, $-NHCONR^9R^{10}$, $-OR^9$, $-NR^9R^{10}$, $-CONR^9R^{10}$ and $-NR^9COR^{10}$; or B is C_{2-4} alkenyl or C_{2-4} alkynyl, each being optionally substituted by a group selected from C_{1-4} alkyl, C_{3-6} cycloalkyl, aryl, heteroaryl and heterocyclyl which group is optionally substituted by one or more halo,
- 25

nitro, cyano, trifluoromethyl, trifluoromethoxy, $-\text{CONHR}^9$, $-\text{CONR}^9\text{R}^{10}$, $-\text{SO}_2\text{R}^{11}$, $-\text{SO}_2\text{NR}^9\text{R}^{10}$, $-\text{NR}^9\text{SO}_2\text{R}^{11}$, $\text{C}_{1-4}\text{alkyl}$ or $\text{C}_{1-4}\text{alkoxy}$; with the provisos that:

when n is 1 and W is NR^1 , CR^1R^2 or a bond; or when n is 0 and W is CR^1R^2 ; then B is a group selected from aryl, heteroaryl and heterocyclyl, where each group is optionally

5 substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo, cyano, $\text{C}_{1-4}\text{alkyl}$ (optionally substituted by R^9 or $\text{C}_{1-4}\text{alkoxy}$ or one or more halo), $\text{C}_{2-4}\text{alkenyl}$ (optionally substituted by halo or R^9), $\text{C}_{2-4}\text{alkynyl}$ (optionally substituted by halo or R^9), $\text{C}_{3-6}\text{cycloalkyl}$ (optionally substituted by R^9 or one or more halo), $\text{C}_{5-6}\text{cycloalkenyl}$ (optionally substituted by halo or R^9), aryl (optionally substituted by halo or

10 $\text{C}_{1-4}\text{alkyl}$), heteroaryl (optionally substituted by halo or $\text{C}_{1-4}\text{alkyl}$), heterocyclyl (optionally substituted by $\text{C}_{1-4}\text{alkyl}$), $-\text{SR}^{11}$, $-\text{SOR}^{11}$, $-\text{SO}_2\text{R}^{11}$, $-\text{SO}_2\text{NR}^9\text{R}^{10}$, $-\text{NR}^9\text{SO}_2\text{R}^{11}$, $-\text{NHCONR}^9\text{R}^{10}$, $-\text{OR}^9$, $-\text{NR}^9\text{R}^{10}$, $-\text{CONR}^9\text{R}^{10}$ and $-\text{NR}^9\text{COR}^{10}$; or B is $\text{C}_{2-4}\text{alkenyl}$ or $\text{C}_{2-4}\text{alkynyl}$, each being optionally substituted by a group selected from $\text{C}_{1-4}\text{alkyl}$, $\text{C}_{3-6}\text{cycloalkyl}$, aryl, heteroaryl and heterocyclyl which group is optionally substituted by one or more halo,

15 nitro, cyano, trifluoromethyl, trifluoromethoxy, $-\text{CONHR}^9$, $-\text{CONR}^9\text{R}^{10}$, $-\text{SO}_2\text{R}^{11}$, $-\text{SO}_2\text{NR}^9\text{R}^{10}$, $-\text{NR}^9\text{SO}_2\text{R}^{11}$, $\text{C}_{1-4}\text{alkyl}$ or $\text{C}_{1-4}\text{alkoxy}$; and

when n is 0 and W is NR^1 or a bond; then B is a group selected from bicyclic aryl, bicyclic heteroaryl and bicyclic heterocyclyl, where each group is optionally substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo,

20 cyano, $\text{C}_{1-4}\text{alkyl}$ (optionally substituted by R^9 or $\text{C}_{1-4}\text{alkoxy}$ or one or more halo), $\text{C}_{2-4}\text{alkenyl}$ (optionally substituted by halo or R^9), $\text{C}_{2-4}\text{alkynyl}$ (optionally substituted by halo or R^9), $\text{C}_{3-6}\text{cycloalkyl}$ (optionally substituted by R^9 or one or more halo), $\text{C}_{5-6}\text{cycloalkenyl}$ (optionally substituted by halo or R^9), aryl (optionally substituted by halo or $\text{C}_{1-4}\text{alkyl}$), heteroaryl (optionally substituted by halo or $\text{C}_{1-4}\text{alkyl}$), heterocyclyl (optionally substituted by $\text{C}_{1-4}\text{alkyl}$),

25 $-\text{SR}^{11}$, $-\text{SOR}^{11}$, $-\text{SO}_2\text{R}^{11}$, $-\text{SO}_2\text{NR}^9\text{R}^{10}$, $-\text{NR}^9\text{SO}_2\text{R}^{11}$, $-\text{NHCONR}^9\text{R}^{10}$, $-\text{OR}^9$, $-\text{NR}^9\text{R}^{10}$, $-\text{CONR}^9\text{R}^{10}$ and $-\text{NR}^9\text{COR}^{10}$; or B is $\text{C}_{2-4}\text{alkenyl}$ or $\text{C}_{2-4}\text{alkynyl}$, each being optionally

substituted by a group selected from $\text{C}_{1-4}\text{alkyl}$, $\text{C}_{3-6}\text{cycloalkyl}$, aryl, heteroaryl and heterocyclyl which group is optionally substituted by one or more halo, nitro, cyano, trifluoromethyl, trifluoromethoxy, $-\text{CONHR}^9$, $-\text{CONR}^9\text{R}^{10}$, $-\text{SO}_2\text{R}^{11}$, $-\text{SO}_2\text{NR}^9\text{R}^{10}$, $-\text{NR}^9\text{SO}_2\text{R}^{11}$, $\text{C}_{1-4}\text{alkyl}$ or

30 $\text{C}_{1-4}\text{alkoxy}$;

R^1 and R^2 are independently hydrogen or a group selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cycloalkyl and C_{5-6} cycloalkenyl which group may be optionally substituted by halo, cyano, hydroxy or C_{1-4} alkoxy;

- R^3 , R^4 , R^5 and R^6 are independently hydrogen or a group selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cycloalkyl, C_{5-6} cycloalkenyl, aryl, heteroaryl and heterocyclyl which group is optionally substituted by one or more substituents independently selected from halo, nitro, cyano, trifluoromethyl, trifluoromethyloxy, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{3-6} cycloalkyl (optionally substituted by one or more R^{17}), aryl (optionally substituted by one or more R^{17}), heteroaryl (optionally substituted by one or more R^{17}), heterocyclyl, $-OR^{18}$, $-SR^{19}$, $-SOR^{19}$, $-SO_2R^{19}$, $-COR^{19}$, $-CO_2R^{18}$, $-CONR^{18}R^{20}$, $-NR^{16}COR^{18}$, $-SO_2NR^{18}R^{20}$ and $-NR^{16}SO_2R^{19}$; or R^1 and R^3 together with the nitrogen or carbon atoms and carbon atom to which they are respectively attached form a saturated 3- to 7-membered ring optionally containing 1 or 2 heteroatom groups selected from NH, O, S, SO and SO_2 where the ring is optionally substituted on carbon by C_{1-4} alkyl, fluoro or C_{1-4} alkoxy and/or on nitrogen by $-COC_{1-3}$ alkyl, $-SO_2C_{1-3}$ alkyl or C_{1-4} alkyl;

- or R^3 and R^4 together form a saturated 3- to 7-membered ring optionally containing 1 or 2 heteroatom groups selected from NH, O, S, SO and SO_2 where the ring is optionally substituted on carbon by C_{1-4} alkyl, fluoro or C_{1-4} alkoxy and/or on nitrogen by $-COC_{1-3}$ alkyl, $-SO_2C_{1-3}$ alkyl or C_{1-4} alkyl;
- or R^5 and R^6 together form a saturated 3- to 7-membered ring optionally containing 1 or 2 heteroatom groups selected from NH, O, S, SO and SO_2 where the ring is optionally substituted on carbon by C_{1-4} alkyl, fluoro or C_{1-4} alkoxy and/or on nitrogen by $-COC_{1-3}$ alkyl, $-SO_2C_{1-3}$ alkyl or C_{1-4} alkyl;

- R^7 is hydrogen or a group selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, heteroalkyl, C_{3-7} cycloalkyl, aryl, heteroaryl or heterocyclyl where the group is optionally substituted by halo, C_{1-4} alkyl, C_{1-4} alkoxy, C_{3-7} cycloalkyl, heterocyclyl, aryl, heteroaryl or heteroalkyl; and wherein the group from which R^7 may be selected is optionally substituted on the group and/or on its optional substituent by one or more substituents independently selected from halo, cyano, C_{1-4} alkyl, nitro, halo C_{1-4} alkyl, heteroalkyl, aryl, heteroaryl, hydroxy C_{1-4} alkyl, C_{3-7} cycloalkyl, heterocyclyl, C_{1-4} alkoxy C_{1-4} alkyl, halo C_{1-4} alkoxy C_{1-4} alkyl, $-COC_{1-4}$ alkyl, $-OR^{21}$, $-CO_2R^{21}$, $-SOR^{25}$, $-SO_2R^{25}$, $-NR^{21}COR^{22}$, $-CONR^{21}R^{22}$ and $-NHCONR^{21}R^{22}$;

-61-

or R^3 and R^7 together with the carbon atoms to which they are each attached and $(CR^5R^6)_n$ form a saturated 5- to 7-membered ring optionally containing a heteroatom group selected from NH, O, S, SO and SO_2 where the ring is optionally substituted on carbon by C_{1-4} alkyl, fluoro or C_{1-4} alkoxy and/or on nitrogen by $-COC_{1-3}$ alkyl, $-SO_2C_{1-3}$ alkyl or C_{1-4} alkyl;

5 R^8 is selected from hydrogen, C_{1-6} alkyl and halo C_{1-6} alkyl;

R^9 and R^{10} are independently hydrogen, C_{1-6} alkyl or C_{3-6} cycloalkyl;

or R^9 and R^{10} together with the nitrogen to which they are attached form a heterocyclic 4 to 7-membered ring.

R^{11} is C_{1-6} alkyl or C_{3-6} cycloalkyl;

10 R^{12} , R^{13} , R^{14} and R^{15} are independently selected from hydrogen, C_{1-6} alkyl and C_{3-6} cycloalkyl;

R^{16} is hydrogen or C_{1-6} alkyl;

R^{17} is selected from halo, C_{1-6} alkyl, C_{3-6} cycloalkyl and C_{1-6} alkoxy;

R^{18} is hydrogen or a group selected from C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{5-7} cycloalkenyl, saturated heterocyclyl, aryl, heteroaryl, aryl C_{1-4} alkyl and heteroaryl C_{1-4} alkyl which group is optionally

15 substituted by one or more halo;

R^{19} and R^{25} are independently a group selected from C_{1-6} alkyl, C_{3-6} cycloalkyl, C_5

7 cycloalkenyl, saturated heterocyclyl, aryl, heteroaryl, aryl C_{1-4} alkyl and heteroaryl C_{1-4} alkyl which group is optionally substituted by one or more halo;

R^{20} is hydrogen, C_{1-6} alkyl or C_{3-6} cycloalkyl;


20 or R^{18} and R^{20} together with the nitrogen to which they are attached form a heterocyclic 4- to 7- membered ring;

R^{21} and R^{22} are independently hydrogen, C_{1-4} alkyl, halo C_{1-4} alkyl, aryl and aryl C_{1-4} alkyl;

or R^{21} and R^{22} together with the nitrogen to which they are attached form a heterocyclic 5- to 6- membered ring.

25

2. A compound of formula (1) or a pharmaceutically acceptable salt thereof:



wherein:

Y^1 and Y^2 are independently O or S;

z is NR^8 , O or S;

n is 0;

5 W is NR^1 ;

m is 0 or 1;

D is hydrogen, C_{1-4} alkyl, C_{3-6} cycloalkyl or fluoro;

X is $-(CR^{12}R^{13})_t-Q-(CR^{14}R^{15})_u-$ where t and u are independently 0 or 1 and Q is O, S, SO or SO_2 ;

10 B is a group selected from aryl, heteroaryl and heterocyclyl, where each group is optionally substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo, cyano, C_{1-4} alkyl (optionally substituted by R^9 or C_{1-4} alkoxy or one or more halo), C_{2-4} alkenyl (optionally substituted by halo or R^9), C_{2-4} alkynyl (optionally substituted by halo or R^9), C_{3-6} cycloalkyl (optionally substituted by R^9 or one or more halo),

15 C_{5-6} cycloalkenyl (optionally substituted by halo or R^9), aryl (optionally substituted by halo or C_{1-4} alkyl), heteroaryl (optionally substituted by halo or C_{1-4} alkyl), heterocyclyl (optionally substituted by C_{1-4} alkyl), $-SR^{11}$, $-SOR^{11}$, $-SO_2R^{11}$, $-SO_2NR^9R^{10}$, $-NR^9SO_2R^{11}$, $-NHCONR^9R^{10}$, $-OR^9$, $-CONR^9R^{10}$ and $-NR^9COR^{10}$;

R^1 is hydrogen or a group selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cycloalkyl and

20 C_{5-6} cycloalkenyl which group may be optionally substituted by halo, cyano, hydroxy or C_{1-4} alkoxy;

R^3 and R^4 are independently hydrogen or a group selected from C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{3-5} cycloalkyl, pentenyl, aryl, heteroaryl and heterocyclyl which group is optionally substituted by one or more substituents independently selected from halo, nitro, cyano,

25 trifluoromethyl, trifluoromethoxy, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{3-6} cycloalkyl (optionally substituted by one or more R^{17}), aryl (optionally substituted by one or more R^{17}), heteroaryl (optionally substituted by one or more R^{17}), heterocyclyl, $-OR^{18}$, $-SR^{19}$, $-SOR^{19}$, $-SO_2R^{19}$, $-CONR^{18}R^{20}$ and $-NR^{16}COR^{18}$;

or R^1 and R^3 together with the nitrogen and carbon atoms to which they are respectively

30 attached form a saturated 3- to 7-membered ring optionally containing 1 or 2 heteroatom groups selected from NH, O, S, SO and SO_2 where the ring is optionally substituted on carbon

by C₁₋₄alkyl, fluoro or C₁₋₄alkoxy and/or on nitrogen by -COC₁₋₃alkyl, -SO₂C₁₋₃alkyl or C₁₋₄alkyl;

or R³ and R⁴ together form a carbocyclic or saturated heterocyclic 3- to 7-membered ring optionally containing 1 or 2 heteroatom groups selected from NH, O, S, SO and SO₂ where

5 the ring is optionally substituted on carbon by C₁₋₄alkyl, fluoro or C₁₋₄alkoxy and/or on nitrogen by -COC₁₋₃alkyl, -SO₂C₁₋₃alkyl or C₁₋₄alkyl;

R⁷ is hydrogen or a group selected from C₁₋₄alkyl, heteroalkyl, C₃₋₅cycloalkyl, aryl, heteroaryl or heterocyclyl which group is optionally substituted by halo, C₁₋₄alkyl, C₁₋₄alkoxy, C₃₋₅cycloalkyl, heterocyclyl, aryl, heteroaryl or heteroalkyl; and wherein the group from which R⁷

10 may be selected is optionally substituted on the group and/or on its optional substituent by one or more substituents independently selected from halo, cyano, C₁₋₄alkyl, nitro, haloC₁₋₄alkyl, heteroalkyl, aryl, heteroaryl, hydroxyC₁₋₄alkyl, C₃₋₅cycloalkyl, heterocyclyl, C₁₋₄alkoxyC₁₋₄alkyl, haloC₁₋₄alkoxyC₁₋₄alkyl, -COC₁₋₄alkyl, -OR²¹, -CO₂R²¹, -SR²⁵, -SOR²⁵, -SO₂R²⁵, -CONR²¹R²² and -NHCONR²¹R²²;

15 or R³ and R⁷ together with the carbon atoms to which they are each attached and (CR⁵R⁶)_n form a saturated carbocyclic or heterocyclic 5- or 6-membered ring;

R⁸ is selected from hydrogen, C₁₋₄alkyl and haloC₁₋₄alkyl;

R⁹ and R¹⁰ are independently hydrogen, C₁₋₆alkyl or C₃₋₆cycloalkyl;

or R⁹ and R¹⁰ together with the nitrogen to which they are attached form a heterocyclic 4 to 6-
20 membered ring.

R¹¹ is C₁₋₄alkyl or C₃₋₅cycloalkyl;

R¹², R¹³, R¹⁴ and R¹⁵ are independently selected from hydrogen, C₁₋₄alkyl and C₃₋₄cycloalkyl;

R¹⁶ is hydrogen or C₁₋₄alkyl;

R¹⁷ is selected from halo, C₁₋₄alkyl, C₃₋₅cycloalkyl and C₁₋₄alkoxy;

25 R¹⁸ is hydrogen or a group selected from C₁₋₄alkyl, C₃₋₅cycloalkyl, C₅₋₆cycloalkenyl, saturated heterocyclyl, aryl, heteroaryl, arylC₁₋₄alkyl and heteroarylC₁₋₄alkyl which group is optionally substituted by one or more halo;

R¹⁹ and R²⁵ are independently a group selected from C₁₋₄alkyl, C₃₋₅cycloalkyl, C₅₋₆cycloalkenyl, saturated heterocyclyl, aryl, heteroaryl, arylC₁₋₄alkyl and heteroarylC₁₋₄alkyl

30 which group is optionally substituted by one or more halo;

R²⁰ is hydrogen, C₁₋₄alkyl or C₃₋₅cycloalkyl;

or R^{18} and R^{20} together with the nitrogen to which they are attached form a heterocyclic 4- to 6- membered ring;

R^{21} and R^{22} are independently hydrogen, C_{1-4} alkyl, halo C_{1-4} alkyl, aryl and aryl C_{1-4} alkyl;

or R^{21} and R^{22} together with the nitrogen to which they are attached form a heterocyclic 5- to

5 6- membered ring.

3. A compound according to claim 1 wherein B is phenyl, naphthyl, pyridyl, quinoliny, isoquinoliny, thienopyridyl, naphthyridinyl, 2,3-methylenedioxyphenyl, 3,4-

methylenedioxyphenyl, thienopyrimidinyl, pyridoimidazolyl, benzimidazolyl, benzofuranyl,

10 benzothienyl, indolyl, benzothiazolyl, benzotriazolyl, benzisoxazolyl, benzisothiazolyl,

indazolyl, indoliziny, isobenzofuranyl, quinazolinyl, imidazopyridinyl, pyrazolopyridinyl,

indoliny, tetrahydroquinoliny, tetrahydroisoquinoliny or isoindoliny, where each is

optionally substituted by one or more groups independently selected from nitro,

trifluoromethyl, trifluoromethoxy, halo, C_{1-4} alkyl (optionally substituted by one or more halo),

15 C_{2-4} alkynyl, heteroaryl, $-OR^9$, cyano, $-NR^9R^{10}$, $-CONR^9R^{10}$ and $-NR^9COR^{10}$; or B is vinyl

or ethynyl optionally substituted by C_{1-4} alkyl.

4. A compound according to claim 1 or 2 wherein B is a group selected from bicyclic

aryl, bicyclic heteroaryl and bicyclic heterocyclyl, where each group is optionally substituted

20 by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy,

halo, C_{1-4} alkyl (optionally substituted by one or more halo), C_{2-4} alkynyl, heteroaryl, $-OR^9$,

cyano, $-NR^9R^{10}$, $-CONR^9R^{10}$ and $-NR^9COR^{10}$; or B is C_{2-4} alkenyl or C_{2-4} alkynyl optionally

substituted by C_{1-4} alkyl, C_{3-6} cycloalkyl or heterocyclyl.


25 5. A compound according to claim 1 or 2 wherein B is 2-methylquinolin-4-yl.

6. A compound according to any one of the preceding claims wherein R^7 is hydrogen or a group selected from C_{1-4} alkyl, aryl C_{1-4} alkyl, heteroaryl C_{1-4} alkyl, heterocyclyl C_{1-4} alkyl, aryl,

heteroaryl, heterocyclyl and C_{3-5} cycloalkyl which group is optionally substituted by cyano, C_{1-}

30 C_{4-} alkyl, halo, $-OR^{21}$, $-NR^{21}R^{22}$, $-CO_2R^{21}$ and $-NR^{21}CO_2R^{22}$.

7. A compound according to claim 6 wherein R^7 is hydrogen or C_{1-4} alkyl optionally substituted with halo, hydroxy or C_{1-3} alkoxy.
8. A pharmaceutical composition comprising a compound according to claim 1 or claim 5 2; and a pharmaceutically-acceptable diluent or carrier.
9. A compound according to claim 1 or 2 for use as a medicament.
10. The use of a compound according to claim 1 or 2 in the manufacture of a medicament 10 in the treatment of a disease condition mediated $TNF-\alpha$.
11. The use of a compound according to claim 1 or 2 in the manufacture of a medicament in the treatment of autoimmune disease, allergic/atopic diseases, transplant rejection, graft versus host disease, cardiovascular disease, reperfusion injury and malignancy in a warm- 15 blooded animal such as man.
12. A method of treating autoimmune disease, allergic/atopic diseases, transplant rejection, graft versus host disease, cardiovascular disease, reperfusion injury and malignancy in a warm-blooded animal, such as man, in need of such treatment which comprises 20 administering to said animal an effective amount of a compound according to claim 1 or 2.
13. A process for preparing a compound according to claim 1 or 2, comprising the steps of converting a ketone or aldehyde of formula (2) into a compound of formula (1);



25

and thereafter if necessary:

- i) converting a compound of formula (1) into another compound of formula (1);
- ii) removing any protecting groups;
- iii) forming a pharmaceutically acceptable salt or *in vivo* hydrolysable ester